Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2012. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share capital and treasury holdings.
- Shares Purchased: 1,600,000 Ordinary Shares on September 3, 2012.
- Price Range: Highest price paid was 1,437.0 pence; lowest price paid was 1,425.0 pence.
- Treasury Holdings (Settled): 499,908,927 shares (9.14% of total issued share capital).
- Treasury Holdings (Including Unsettled): 504,608,927 shares (10.15% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,972,322,982 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,600,000 shares for treasury. This action increased the percentage of shares held in treasury from the prior level to 9.14% of issued capital (or 10.15% of voting rights including unsettled shares).
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (4,972,322,982) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current percentage of voting rights held in treasury (10.15% including unsettled shares).
- Note that the filing does not contain operational or financial performance data for the period.